Postdiarrheal hemolytic uremic syndrome in United States children: clinical spectrum and predictors of in-hospital death

J Pediatr. 2015 Apr;166(4):1022-9. doi: 10.1016/j.jpeds.2014.12.064. Epub 2015 Feb 4.

Abstract

Objective: To assess the clinical spectrum of postdiarrheal hemolytic uremic syndrome (D(+)HUS) hospitalizations and sought predictors of in-hospital death to help identify children at risk of poor outcomes.

Study design: We assessed clinical variables collected through population-based surveillance of D(+)HUS in children <18 years old hospitalized in 10 states during 1997-2012 as predictors of in-hospital death by using tree modeling.

Results: We identified 770 cases. Of children with information available, 56.5% (430 of 761) required dialysis, 92.6% (698 of 754) required a transfusion, and 2.9% (22 of 770) died; few had a persistent dialysis requirement (52 [7.3%] of 716) at discharge. The tree model partitioned children into 5 groups on the basis of 3 predictors (highest leukocyte count and lowest hematocrit value during the 7 days before to 3 days after the diagnosis of hemolytic uremic syndrome, and presence of respiratory tract infection [RTI] within 3 weeks before diagnosis). Patients with greater leukocyte or hematocrit values or a recent RTI had a greater probability of in-hospital death. The largest group identified (n = 533) had none of these factors and had the lowest odds of death. Many children with RTI had recent antibiotic treatment for nondiarrheal indications.

Conclusion: Most children with D(+)HUS have good hospitalization outcomes. Our findings support previous reports of increased leukocyte count and hematocrit as predictors of death. Recent RTI could be an additional predictor, or a marker of other factors such as antibiotic exposure, that may warrant further study.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adolescent
  • Anti-Bacterial Agents / therapeutic use
  • Child
  • Child, Preschool
  • Diarrhea / complications*
  • Diarrhea / therapy
  • Escherichia coli Infections / complications
  • Escherichia coli Infections / therapy
  • Female
  • Fluid Therapy
  • Follow-Up Studies
  • Hemolytic-Uremic Syndrome / epidemiology*
  • Hemolytic-Uremic Syndrome / etiology
  • Hemolytic-Uremic Syndrome / therapy
  • Hospital Mortality / trends
  • Humans
  • Infant
  • Male
  • Population Surveillance / methods*
  • Prognosis
  • Retrospective Studies
  • Risk Factors
  • United States / epidemiology

Substances

  • Anti-Bacterial Agents